Table 3.
Exploration of a putative prognostic effect of the NLR on survival in ALS using multivariable Cox regression analyses
| Variables | HR (95% CI) | P-value |
|---|---|---|
| NLR (continuous)a | 1.079 (1.016–1.146) | 0.014 |
| NLR (continuous)b | 1.074 (1.012–1.141) | 0.019 |
| NLR (categorized)a | ||
| 1.000 (Ref) | ||
| 1.101 (0.925–1.311) | 0.277 | |
| 1.249 (1.015–1.537) | 0.035 | |
| P trend | 0.033 | |
| NLR (categorized)b | ||
| 1.000 (Ref) | ||
| 1.137 (0.954–1.355) | 0.152 | |
| 1.250 (1.013–1.541) | 0.037 | |
| P trend | 0.026 | |
| NLR (continuous)c | 1.082 (1.021–1.46) | 0.007 |
| NMR (continuous)d | 1.015 (1.000–1.030) | 0.045 |
aAdjusted for age, sex, stage, phenotype, onset region, BMI, ALSFRS-R, disease duration, albumin, and HbA1c; bAdjusted for age, sex, stage, phenotype, onset region, BMI, ALSFRS-R, disease duration, albumin, HbA1c, and treatment; cUsing time since registration instead of time since symptom onset, and adjusted for age, sex, stage, phenotype, onset region, BMI, ALSFRS-R, disease duration, albumin, and HbA1c; dUsing NMR instead of NLR, and adjusted for age, sex, stage, phenotype, onset region, BMI, ALSFRS-R, disease duration, albumin, and HbA1c. ALS: Amyotrophic lateral sclerosis; ALSFRS-R: Revised Amyotrophic Lateral Sclerosis Functional Rating Scale; BMI: body mass index; CI: confidence interval; HbA1c: hemoglobin A1c; HR: hazard ratio; NLR: neutrophil-to-lymphocyte ratio; NMR: neutrophil-to-monocyte ratio.